Kane technology is a provider of treatment solutions in the field of viral diseases. The company actively develops innovative drugs on the basis of producing and selling existing therapeutic drugs in the field of viral diseases. The company is the first pharmaceutical company in China to successfully develop a pan-genotype all-oral drug combination with high cure rate of hepatitis C, breaking the monopoly of foreign pharmaceutical companies on domestic hepatitis C treatment drugs. The company has a number of mature commercial varieties, including recombinant human interferon α2b and compound glycyrrhizin, which are mainly used to treat viral diseases. The company has built a research and development platform for antiviral drugs in the whole industry chain, covering the whole chain from discovery and development to production and commercialization, and successfully developed a number of innovative drugs on this basis.
More peer analysis, the company knows and understands.